Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages 54-68 , July 2008

Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients

  • Margaret K. Vernon, PhD

      Affiliations

    • United BioSource Corporation, Center for Health Outcomes Research, Bethesda, Maryland
    • Corresponding Author InformationAddress correspondence to: Margaret K. Vernon, PhD, United BioSource Corporation, Center for Health Outcomes Research, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA.
    • ,
  • Nancy A. Brandenburg, PhD

      Affiliations

    • Pfizer, Inc., New York, New York, USA
    • ,
  • Jose Ma. J. Alvir, DrPH

      Affiliations

    • Pfizer, Inc., New York, New York, USA
    • ,
  • Teresa Griesing, PhD

      Affiliations

    • Pfizer, Inc., New York, New York, USA
    • ,
  • Dennis A. Revicki, PhD

      Affiliations

    • United BioSource Corporation, Center for Health Outcomes Research, Bethesda, Maryland

,Accepted 11 September 2007.

References 

  1. Neuropathy Association . Available at http://www.neuropathy.orgAccessed April 27, 2007
  2. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–1522
  3. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976–982
  4. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123–128
  5. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374–385
  6. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2006;22:681–685
  7. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol. 2005;99:2008–2019
  8. Kawakami N, Takatsuka N, Shimizu H. Sleep disturbance and onset of type 2 diabetes. Diabetes Care. 2004;27:282–283
  9. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 2000;61:2437–24442447–2438
  10. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol. 1986;20:651–664
  11. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321:794–796
  12. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–363
  13. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing. 2006;35:132–137
  14. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197
  15. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41–44
  16. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45:3–9discussion 1–2
  17. Watson C. Neuropathic pain syndromes. New York, NY: Raven Press, Ltd.; 1991;
  18. Jensen MP, Karoly P. Pain-specific beliefs, perceived symptom severity, and adjustment to chronic pain. Clin J Pain. 1992;8:123–130
  19. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–638
  20. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–2110
  21. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253–260
  22. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254–263
  23. Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs. 2004;64:2813–2820discussion 2821
  24. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: Department of Health, Education and Welfare; 1976;
  25. Fischer D, Stewart AL, Bloch DA, et al. Capturing the patient's view of change as a clinical outcome measure. JAMA. 1999;282:1157–1162
  26. Collins SL, Edwards J, Moore RA, Smith LA, McQuay HJ. Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?. Pain. 2001;91:189–194
  27. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158
  28. Ware JE, Snow KK, Kosinski MK, Gandek B. SF-36 Health Survey: Manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993;
  29. McNair D, Lorr M, Droppleman L. Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Services; 1971;
  30. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–343
  31. Hays RD, Revicki DA. Reliability and validity (including responsiveness). In:  Fayers P,  Hays RD editor. Assessing quality of life in clinical trials: Methods and practice. 2nd ed.. Oxford: Oxford University Press; 2005;p. 25–39

 This study was supported by funding from Pfizer, Inc.

PII: S0885-3924(08)00142-5

doi: 10.1016/j.jpainsymman.2007.09.016

Journal of Pain and Symptom Management
Volume 36, Issue 1 , Pages 54-68 , July 2008

Article Tools

* Image Usage & Resolution